Groupe d'Etude en Oncologie du Quebec

Title	A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor
Protocole ID	ARTEMIA
ClinicalTrials.gov ID	NCT06472245
Cancer Type(s)	Non Small Cells - Lung
Phase	Phase III
Stage
Study Type	Clinical
Drug	OSE2101 versus docetaxel
Institution	CISSS DU BAS-SAINT-LAURENT HOPITAL REGIONAL DE RIMOUSKI 150 av. Rouleau, Rimouski, QC, G5L 5T1
City
Principal Investigator	Dr. Marie-Claude Foley
Coordinator	Isabelle Gagnon 418-724-3000 poste 8029
Status	Recruiting
Activation Date
Eligibility Criteria	Male or female, aged ≥ 18 years Patients expressing HLA-A2 phenotype in blood by pre-screening central laboratory Patients with histologically or cytologically squamous or non-squamous documented NSCLC, metastatic stage at study entry, not eligible for definite surgery or radiation, without EGFR, ALK and ROS1 gene alterations eligible for targeted therapy; other sensitizing mutations known to be immunosensitive are eligible in case of lack of local access to targeted therapy (i.e.; KRAS G12C and BRAF mutations) after Sponsor's agreement Patients with secondary resistance to ICI; Other inclusion and exclusion criteria will apply per protocol.
Exclusion Criteria

Groupe d'étude en oncologie du Québec